JGJessica González

Jessica González

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jessica González has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of Two Deep Learning Models and Their Combination for 1-year Lung Cancer Detection in Two Screening Cohorts

    by Anthony P. Reeves, Mohammad Mozafary, Ali Hashemi, Kyle Atlas, Chenyu Zhang, Thomas Atlas, Amir Azimi, Seyed Reza Mirjalili, Rowena Yip, Rozemarijn Vliegenthart, et al.

    Sybil and a Medical Open Network for Artificial Intelligence (MONAI)–based nodule model demonstrated stable discrimination for 1-year lung cancer detection across geographically distinct screening cohorts. A prespecified combination of Sybil and MONAI-derived nodule features achieved high-sensitivity triage while correctly classifying a substantial proportion of noncancer baseline low-dose CT examinations as negative.

  • Open Access

    A prospective cohort study for characterization and predictive factors of long-term POST-COVID interstitial changes

    by M. Hernandez-Argudo, J. Bordas-Martinez, V. Vicens-Zygmunt, G. Bermudo, G. Suarez-Cuartin, B. del Rio, S. Bolivar, H. Jofre-Grimaldo, R. Llatjós, L. Pijuan, et al.

    Chronic interstitial lung changes are potential long-term sequelae of severe COVID-19. This study aims to evaluate the prevalence and type of interstitial changes over time and identify serum biomarkers associated with persistent lung abnormalities. Prospective, multicenter, observational cohort study of patients with severe COVID-19 pneumonia between March 2020 and June 2021. Clinical evaluation, pulmonary function tests (PFTs), and chest high-resolution computed tomography (HRCT) were performed at baseline and up to 24 months. Serum biomarkers were assessed at baseline and at 12 months. Of the 290 patients enrolled, 247 completed the follow-up. Mild dyspnea (mMRC1) was the most common residual symptom. PFTs showed significant improvement: mean FVC increased from 88.8% to 99.5%, and DLCO from 71.6% to 82%. Among patients with baseline DLCO < 80% (n = 67), only 38.8% achieved normalization. Radiological improvement was observed in all patients, though 32% of the 118 patients assessed at 24 months still had residual changes, primarily mild reticulation, ground glass opacities, and lower lobes traction bronchiectasis. Pulmonary functional improvement correlated with radiological resolution, especially during the first year. Elevated baseline levels of MMP-7 and KL6 were associated with persistent interstitial abnormalities at 12 months. Severe COVID-19 survivors exhibit progressive functional and radiological improvement, particularly within the first year. However, a subset of patients shows long-term interstitial changes. Elevated MMP-7 and KL-6 levels may help identify individuals at higher risk for persistent interstitial changes.


  • Linking Lungs and Heart

    by Jessica González, Rowena Yip, Jiafang Zhang, Artit Jirapatnakul, David F. Yankelevitz, Claudia I. Henschke


  • Open Access

    Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate After Dual and Triple Therapy in Spain: A Sub-Study of the ORESTES Study

    by Juan Marco Figueira-Gonçalves, Bernardino Alcázar-Navarrete, Raquel Casitas-Mateo, Jessica González, Carolina María Gotera-Rivera, Alberto Herrejón-Silvestre, Juan Margallo-Iribarnegaray, Marta Martín-Lana, Abel Pallarés-Sanmartín, Sergi Pascual-Guardia, et al.

    Introduction Chronic obstructive pulmonary disease (COPD) is a progressive lung condition associated with high morbidity and mortality. Single-inhaler triple therapy (SITT), such as budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF), is recommended for patients with COPD who are not adequately controlled by dual therapy (DT). Escalation from DT or switching from triple therapy (TT)—SITT or multiple-inhaler TT (MITT)—are key real-world treatment pathways. Methods The observational, retrospective, multicenter ORESTES study included adults (≥ 40 years) with COPD initiating BGF in routine clinical practice. This secondary analysis focuses on the following treatment pathways: escalation from DT and switch from TT. Patients’ characteristics, exacerbations, additional COPD treatments, and healthcare resource utilization (HCRU) were assessed. Results A total of 295 patients escalated from DT and 356 switched from TT (SITT: 147; MITT: 209) to BGF. 66.8% of patients escalating from DT and 78.5% switching from TT showed a high-risk GesEPOC phenotype; 77.9% and 80.0% had mMRC grade ≥ 2, and 91.2% and 96.1% had ≥ 3 comorbidities. Following BGF initiation, the annualized exacerbation rate decreased by 11.6% (from 1.06 to 0.94) in patients escalating from DT and by 15.5% (from 1.60 to 1.35) in patients switching from TT (after SITT: 17.8% reduction; after MITT: 14.1%). Rescue medication use declined overall, and specifically short-acting beta-2 agonists (SABA) use declined by 23.2% and 19.4% (SITT: 21.9%; MITT: 18.4%). Emergency room visits and hospitalizations decreased by 19.7% and 19.0% in patients escalating from DT, and by 29.4% and 25.5% among those switching from TT (SITT: 25.0%/18.3%; MITT: 32.4%/29.9%). Conclusions In this real-world Spanish cohort of patients with COPD not adequately controlled with DT or TT, reductions in exacerbations, rescue medication use, and HCRU were observed after BGF initiation, supporting the potential value of earlier introduction of BGF in patients with persistent symptoms and/or frequent exacerbations despite high-intensity therapy. Clinical Trial Registration NCT06321731.


  • Open Access

    Comprehensive maintenance program: a health haven for chronic obstructive pulmonary disease in Lleida, Spain

    by Jessica González Gutiérrez, Anna Sánchez Cucó, Aida Monge Esqué

  • Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later

    by Jessica González Gutiérrez, Rowena Yip, Javier J Zulueta, Samuel M Aguayo, Daniel M Libby, Mark W Pasmantier, David F Yankelevitz, Claudia I Henschke, International Early Lung Cancer Action Program Investigators

    Emphysema identified at baseline low-dose CT in a lung cancer screening program was predictive of all-cause, chronic obstructive pulmonary disease, and cardiovascular disease mortality 25 years later in 9047 asymptomatic adults with a smoking history.


  • Open Access

    Long-Term Outcomes of Critically Ill Survivors of COVID-19

    by María Zuil, Anna Vila-Fornells, Sally Santisteve, Rafaela Vaca, Maria Aguilà, Aida Monge, Anna Sánchez-Cucó, Iván D. Benítez, Nuria Forns, Olga Minguez, et al.

  • Open Access

    Multidisciplinary virtual management of pulmonary nodules

    by D. Polanco, J. González, E. Gracia-Lavedan, L. Pinilla, R. Plana, M. Molina, M. Pardina, F. Barbé

    Multidisciplinary nodule clinics provide high-quality care and favor adherence to guidelines. Virtual care has shown savings benefits along with patient satisfaction. Our aim is to describe the first year of operation of a multidisciplinary virtual lung nodule clinic, the population evaluated and issued decisions. Secondarily, among discharged patients, we aimed to analyze their follow-up prior to the existence of our consultation, evaluating its adherence to guidelines. Observational study including all patients evaluated at the Virtual Lung Nodule Clinic (VLNC) (March 2018- March 2019). Clinical and radiological data were recorded. Recommendations, based on 2017 Fleischner Society guidelines, were categorized into follow-up, discharge or referral to lung cancer consultation. Discharged patients were classified according to adherence to guidelines of their previous management, into adequate, prolonged and non-indicated follow-up. A total of 365 patients (58.9% men; median age 64.0 years) were included. Sixty-four percent had smoking history and 23% had chronic obstructive pulmonary disease (COPD). Most nodules were solid (87.4%) and multiple (57.5%). The median diameter was 6.00 mm. 43.8% of patients were discharged following first VLNC evaluation. Among them, 27.5% had received appropriate follow-up, but 66.9% had received poor management. Patients with prolonged follow-up (33.1%) were older (67.0 vs 60.5 years) and had larger nodules (6.00 mm vs 5.00). Non-indicated follow-up patients (33.8%) were more non-smokers (77.8% vs 31.8%) and presented smaller nodules (4.00 vs 5.00 mm). During its first year of operation, the VLNC has evaluated a population with a relevant risk profile for lung cancer development, management of which should be cautious and adhere to guidelines. After the first VLNC assessment, approximately one-half of this population was discharged. It was noticeable that previous follow-up of discharged patients was found poorly adherent to guidelines, with a marked tendency to overmanagement.


  • Panta rhei (Πάντα ῥεῖ), or everything flows with long COVID

    by Joan B. Soriano, Jessica González, Antoni Torres

    No long COVID patient ever steps in the same river twice, as their condition changes continuously due to its natural history, or because of treatment http://bit.ly/3QMFhyK


  • Sleep and circadian health 6 months after critical COVID‐19 disease

    by Adriano D. S. Targa, Iván D. Benítez, Jessica González, Gerard Torres, Sally Santisteve, Rafaela Vaca, Olga Minguez, Maria Aguilà, Paola Carmona, Anna Moncusí‐Moix, et al.